Navigation Links
Loyola physician helps develop national guidelines for osteoporosis
Date:1/24/2011

MAYWOOD, Ill. -- The American Association of Clinical Endocrinologists (AACE) has released new medical guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Loyola physician Pauline Camacho, MD, was part of a committee that developed the guidelines to manage this major public health issue.

These recommendations were developed to reduce the risk of osteoporosis-related fractures and improve the quality of life for patients. They explain new treatment options and suggest the use of the FRAX tool (a fracture risk assessment tool developed by the World Health Organization) and the National Osteoporosis Foundation guide to identify candidates for treatment.

"Less than one-third of osteoporosis cases are diagnosed, and only one-seventh of American women with osteoporosis receive treatment," said co-author Pauline Camacho, MD, director of the Loyola University Osteoporosis and Metabolic Bone Disease Center. "These guidelines use evidence to help physicians better identify and care for these women."

More than 10 million Americans have osteoporosis and approximately 35 million more have low bone mass and are at increased risk for developing osteoporosis and fractures. Approximately 80 percent of these are women, most of them postmenopausal. AACE recommends that high-risk postmenopausal women should be screened immediately and all women ages 65 and older should be tested routinely for the disease.

Hip fractures are the most serious complication of osteoporosis. Half of all patients who could walk independently are unable to do so one year after a hip fracture. A hip fracture leads to an increased mortality rate for two years following the break. More than half of the survivors are unable to return to independent living and many require long-term nursing home care.

"These guidelines take into consideration the economic impact of the disease," Dr. Camacho said. "They stress the need for efficient and effe
'/>"/>

Contact: Nora Plunkett
nplunkett@lumc.edu
708-216-6268
Loyola University Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Loyola among worlds top centers in pathology competition
2. Chicago Trial Attorney Inducted as Loyola University Chicago School of Law's First Cooney & Conway Chair in Advocacy
3. Louisiana's First DNP Program Kicks Off Classes at Loyola University New Orleans
4. MedPage Today(R) What Your Physicians Are Reading
5. The Case for the iPad: Mobile Charge Capture for Physicians
6. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
7. Orthopaedic Physician Dr. Brett Smith Joins Baptist Health Care as Total Joint Specialist
8. WebMD Launches New Version of Free Mobile Application for Physicians
9. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
10. Global Medical Staffing Extends Locum Tenens Physician Placement to the Middle East
11. Pay-for-performance programs show positive impact on low-performing physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... one out of every 40 individuals in the United States ... atrophy (SMA), a neurodegenerative disease that causes muscles to weaken ... made a recent breakthrough with the development of a new ... the disease. In April, a patent was filed for the ... is using to fight SMA is to ,repress the repressor," ...
(Date:9/15/2014)... September 15, 2014 In order to ... medicine often act conjointly to quantify, define and model ... become an integral part of medical care. , The ... the studies conducted by the non-profit Institute of BioAcoustic ... demonstrated that math can be much more than a ...
(Date:9/15/2014)... Dennis Thompson ... News) -- The severe respiratory virus believed to have ... states has now spread to the Northeast, health officials ... confirmed on Friday more than a dozen cases of ... for children with asthma. And on Saturday, the ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 As ... end of its first full year, there are ... maturing; especially in the evolution of its marketing ... approach being taken by Denver's Kindman, one of ... and distributors. , Kindman has pioneered the first-ever ...
(Date:9/15/2014)... September 15, 2014 As Risperdal lawsuits ... Bernstein Liebhard LLP notes that a new study has ... curbing aggression in children with ADHD when it is ... in behavioral management techniques. According to a report from ... and aggression problems, half of whom took Concerta, a ...
Breaking Medicine News(10 mins):Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4
... 2008) University of Minnesota researchers have created a beating ... called whole organ decellularization, scientists from the University of Minnesota ... dead rat and pig hearts and reseeding them with a ... in the January 13 issue of Nature Medicine., The ...
... injected into ,skeleton, of animal organ was beating in ... -- An organ-building biotechnology that could create transplantable hearts ... important laboratory tests, researchers report. , The technique, called ... heart tissue, according to a report in the Jan. ...
... here today," says James, a ClearChoices speaker. "I was,addicted ... I was at dinner each,night... they thought everything was ... and prevent them from going through what I went ... Chrysler LLC and,Barrett- Jackson will allow notMYkid to educate ...
... 500 Executive Driving Global Breast Cancer Leader,s Promise ... End Breast Cancer Forever, ATLANTA, Jan. 12 Hala ... the global leader in the fight to end breast,cancer forever, ... annual Trumpet Awards event in Atlanta with a ,High Heels ...
... LAUDERDALE, Fla., Jan. 11 eDiets.com,Inc. (Nasdaq: DIET ... Hamilton. Mr. Hamilton, who joined the Company in November,1999, ... privately held,company. Mr. Hamilton will remain available to assist ... firm to find a replacement and has,appointed Carla Cox, ...
... CHAPEL HILL, N.C., Jan. 11 Today,s top-level,pharmaceutical ... the,team that will carry out the plan as ... study by pharmaceutical research firm, Best,Practices, LLC., ... looking to invest people and money earlier in ...
Cached Medicine News:Health News:U of M researchers create beating heart in laboratory 2Health News:Biotechnology Builds a New Heart 2Health News:Biotechnology Builds a New Heart 3Health News:First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 2Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 3Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2
(Date:9/15/2014)... SINGAPORE , Sept. 15, 2014  Catalist-listed QT ... "the Group"), a developer and manufacturer of minimally invasive ... pleased to announce that the Group has enrolled the ... Germany . Multiple patients have already been ... , at Auckland City Hospital, in Auckland, ...
(Date:9/15/2014)... Sept. 15, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... paid the September 12, 2014, regular quarterly dividend payment of ... PDL as of September 5, 2014, the record date. ... manages a portfolio of patents and royalty assets, consisting ... and license agreements with various biotechnology and pharmaceutical companies. ...
(Date:9/15/2014)... , Sept. 15, 2014 Research and ... "Closed Drug Transfer Systems to 2020" report to ... deemed hazardous to humans has been receiving increasing amounts ... these substances become more clearly understood. For caregivers and ... forefront of attempts to mitigate exposure to cytotoxic drugs ...
Breaking Medicine Technology:First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3
... Doubled Time to Progression and Overall Response Rate as ... in Patients with 2nd or 3rd Line Metastatic Colon ... KERX ) today announced data on the ... cancer, in combination with capecitabine as a treatment for ...
... increase the risk of breast cancer recurrence , ... found that taking tamoxifen with certain antidepressants more than ... taking both medications. The antidepressants inhibit an enzyme, CYP2D6, ... ) , , The study ...
Cached Medicine Technology:Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6New Research Shows Antidepressants May Thwart Breast Cancer Treatment 2New Research Shows Antidepressants May Thwart Breast Cancer Treatment 3
... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
... Tissue Anchor 2 mm is a resorbable repair ... using sutures. The resorbable repair device is implanted ... is used to reattach damaged soft tissue. The ... derived from glycolide and lactide colored with D&C ...
... of anchor is generally used when ... This 2.9mm anchor is packaged sterile ... or 2-0) and needles. Although pre-drilling ... the Mini Harpoon®, 1.6mm & 1.8mm ...
The MINI-TAG™ instrument systems are indicated for ulnar collateral ligament repair, scapholunate dissolution, flexor avulsions, and carpometa-carpal arthroplasty....
Medicine Products: